

**S-Figure 1.** Experimental data for the functional validation of the loops in ten most widely reported miRNA-mRNA interactions. Experimental validation for the effects of the wild type and mutant loops on expression levels of target mRNAs and proteins translated by the target mRNAs, respectively.



**S-Figure 2.** The virtual screening model by combining both knowledge-based and structure-based approaches for targeting miRNA-mRNA interaction. a) The schematic diagram of the knowledge-based virtual screening approach. b) The schematic diagram of the structure-based virtual screening approach. c) The weight-lasso scoring system to combine the knowledge-based and structure-based possibilities to rank the molecule candidates.



**S-Figure 3.** Binding assay of the small molecule candidates with the loops. a) Pull-down assay was performed using streptavidin magnetic bead to examine the interaction between biotin-miR-214-ATF4 loop and small molecule OB-5, OB-6, OB-7, OB-8, OB-9, and OB-10. Small molecule OB-5, OB-6, OB-7, OB-8, OB-9, and OB-10 captured by biotin-miR-214-ATF4 loop was examined by LC-MS, respectively (from top to bottom). b) Pull-down assay was performed using streptavidin magnetic bead to examine the interaction between biotin-miR-214-TRAF3 loop and small molecule OC-4, OC-5, OC-6, OC-7, OC-8, OC-9, and OC-10. Small molecule OC-4, OC-5, OC-6, OC-7, OC-8, OC-9, and OC-10. Small molecule OC-4, OC-5, OC-6, OC-7, OC-8, OC-9, and OC-10 captured by biotin-miR-214-TRAF3 loop was examined by LC-MS, respectively (from top to bottom).



**S-Figure 4.** Establishment of stably expressing miR-214 MC3T3-E1 and RAW 264.7 cells. a) Expression of miR-214 in MC3T3-E1 cells infected with miR-214 lentivirus (indicated as Lv-miR-214) and control lentivirus (indicated as Lv-control) was measured by qRT-PCR. b) Expression of miR-214 in RAW 264.7 cells infected with miR-214 lentivirus (indicated as Lv-miR-214) and control lentivirus (indicated as Lv-miR-214).





**S-Figure 6.** MTT assay was used to determine the non-toxic concentration of the small molecule OB-1, OB-2, OB-3, OB-4, respectively, after treatment of MC3T3-E1 cells for 72 h. \*P < 0.05 vs control group.



**S-Figure 7.** Determination of the expression of ATF4 downstream molecules after small molecule OB-4 treatment by Western blot. Representative Western blot (left) and quantification (right) of osteocalcin protein level in MC3T3-E1 cells after treatment with the small molecule OB-4 at 80 nM or vehicle for 48 h. \*\*P < 0.01 vs control group.



**S-Figure 8.** MTT assay was used to determine the non-toxic concentration of the small molecule OC-1, OC-2, or OC-3, respectively, after treatment of RAW 264.7 cells for 72 h. \*P < 0.05 vs control group.



**S-Figure 9.** Determination of the expression of TRAF3 downstream molecules after small molecule OC-3 treatment by Western blot. Representative Western blot (left) and quantification (right) of p65 protein level in RAW 264.7 cells after treatment with the small molecule OC-3 at 6  $\mu$ M or vehicle for 48 h. \*\**P* < 0.01 vs control group.





**S-Figure 10.** Determination of the specificity of OB-4 by LC-MS, Western blot, and PCR. a, d, g, j, m, p, s, v) Pull-down assay was performed using streptavidin magnetic bead to examine the interaction between loops formed by miR-214 and its other target mRNA, Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1, and small molecule OB-4. Small molecule OB-4 captured by loops formed by miR-214 and its other target mRNA, Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1, was examined by LC-MS. b, e, h, k, n, q, t, u) Representative Western blot (left) and quantification (right) of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 protein level in MC3T3-E1 cells after treatment with the small molecule OB-4 at 80 nM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in MC3T3-E1 cells after treatment with the small molecule OB-4 at 80 nM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in MC3T3-E1 cells after treatment with the small molecule OB-4 at 80 nM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in MC3T3-E1 cells after treatment with the small molecule OB-4 at 80 nM or vehicle for 48 h. c





**S-Figure 11.** Determination of the specificity of OC-3 by LC-MS, Western blot, and PCR. a, d, g, j, m, p, s, v) Pull-down assay was performed using streptavidin magnetic bead to examine the interaction between loops formed by miR-214 and its other target mRNA, Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1, and small molecule OC-3. Small molecule OC-3 captured by loops formed by miR-214 and its other target mRNA, Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1, was examined by LC-MS. b, e, h, k, n, q, t, u) Representative Western blot (left) and quantification (right) of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 protein level in RAW 264.7 cells after treatment with the small molecule OC-3 at 6 μM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in RAW 264.7 cells after treatment with the small molecule OC-3 at 6 μM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in RAW 264.7 cells after treatment with the small molecule OC-3 at 6 μM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in RAW 264.7 cells after treatment with the small molecule OC-3 at 6 μM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in RAW 264.7 cells after treatment with the small molecule OC-3 at 6 μM or vehicle for 48 h. c, f, i, l, o, r, u, x) Real-time PCR analysis of Osterix, PTEN, FGFR1, β-catenin, PDRG, FOXM1, CDC25B, CUG-BP1 mRNA level in RAW 264.7 cells after treatment with the small molecule OC-3 at 6 μM or vehicle for 48 h.



**S-Figure 12.** Determination of the binding of OB-4 and OC-3 to miR-214-ATF4 and miR-214-TRAF3 loop, respectively, by ITC and SPR. a) A total of 50 μM of miR-214-ATF4 loop (left) and miR-214-TRAF3 loop (right), respectively, was titrated against 0.5 mmol/L of small molecule OB-4 and OC-3, respectively. The resulting thermograms were analyzed based on the one set of binding sites model using Microcal Origin 7.0 (Microcal. Inc.). b) SPR analysis of the interaction of miR-214-ATF4 loop (left) and miR-214-TRAF3 loop (right) to small molecule OB-4 and OC-3, respectively. Small molecule OB-4 and OC-3, respectively, was added at 20 μM (red), 10 μM (pink), 5 μM (blue), 2.5 μM (orange), and 1.25 μM (green).



The postulated interaction mechanism of the predicted small molecule with AGO and loop

**S-Figure 13.** Proposed interaction mechanisms of predicted small molecule targeting the miRNA-mRNA loop. (Upper) miRNAs guide the AGO to the 3'-untranslated regions (3'-UTR) of target mRNAs and form miRNA-mRNA loops. AGO then cleaves mRNAs. (Down) The predicted small molecule could either interfere the loop formation of the miRNA with the target mRNA when

the miRNA directed the AGO to the target mRNA or directly target the AGO-mediated miRNA-mRNA loop and this targeting could sterically interfere AGO nearby to rescue the repression of mRNA translation by AGO.



**S-Figure 14.** Formation of loop region. a) The miRNAs target mRNAs via base-pairing. The paired NAs form stem region, whereas the unpaired NAs form different loop regions. b) To identify the loop using our computation strategy, the sequence of the miRNA and its target mRNA was firstly input, then the unpaired bases (loops) was generated by the RNAfold program.

| miRNAs       | OA       | WEIGHT | PVALUE      | QVALUE     |  |
|--------------|----------|--------|-------------|------------|--|
| hsa-miR-155  | CEBPB    | 37.8   | 0.000000125 | 0.0000075  |  |
| hsa-miR-145  | FSCN1    | 38.2   | 0.00000155  | 0.0000099  |  |
| hsa-miR-21   | PDCD4    | 38.6   | 0.00000185  | 0.00000123 |  |
| hsa-miR-34a  | E2F3     | 35.4   | 0.00000215  | 0.00000147 |  |
| hsa-miR-125b | TP53INP1 | 32.2   | 0.00000245  | 0.00000171 |  |
| hsa-miR-29a  | MCL1     | 29.0   | 0.00000275  | 0.00000195 |  |
| hsa-miR-29b  | MCL1     | 25.8   | 0.00000305  | 0.00000219 |  |
| hsa-miR-200c | ZEB1     | 27.5   | 0.00000335  | 0.00000243 |  |
| hsa-miR-24   | CDKN1B   | 29.2   | 0.00000365  | 0.00000267 |  |
| hsa-miR-124  | CDK6     | 30.9   | 0.00000395  | 0.00000291 |  |
|              |          |        |             |            |  |

S-Table 1. Ten most widely reported miRNAs in meta-analysis based on PubMed library.

S-Table 2. Ten most widely validated miRNA-mRNA interactions in meta-analysis based on PubMed library.

| miRNA        | Targets  | RA | WB | PCR | MA | NGS | pSILAC | OT | Ref |
|--------------|----------|----|----|-----|----|-----|--------|----|-----|
| hsa-miR-155  | CEBPB    | Y  | Y  | Y   | Y  | Ν   | Y      | Ν  | 27  |
| hsa-miR-145  | FSCN1    | Υ  | Y  | Y   | Υ  | Ν   | Ν      | Y  | 27  |
| hsa-miR-21   | PDCD4    | Y  | Y  | Y   | Y  | Y   | Ν      | Y  | 27  |
| hsa-miR-34a  | E2F3     | Y  | Y  | Y   | Y  | Y   | Ν      | Y  | 27  |
| hsa-miR-125b | TP53INP1 | Υ  | Y  | Y   | Υ  | Y   | Ν      | Y  | 27  |
| hsa-miR-29a  | MCL1     | Y  | Y  | Y   | Y  | Y   | Ν      | Y  | 27  |
| hsa-miR-29b  | MCL1     | Y  | Y  | Y   | Y  | Y   | Ν      | Y  | 27  |
| hsa-miR-200c | ZEB1     | Y  | Y  | Y   | Y  | Y   | Ν      | Y  | 27  |
| hsa-miR-24   | CDKN1B   | Y  | Y  | Y   | Y  | Y   | Ν      | Y  | 27  |
| hsa-miR-124  | CDK6     | Y  | Y  | Y   | Y  | Y   | Ν      | Y  | 27  |

| RNA_ID    | item   | mRNA-miRNA sequence and<br>predicted secondary structures  |  |  |
|-----------|--|--|--|--|
| miRmR_1   | mRNA-miRNA<br>sequence<br>RNAfold<br>Mfold<br>AveRNA | GAGACGGAGGGCCCAUGGAACUUACAGAAGAAGUUGUUGAUGAGUUCAU<br>GGAAGAUGUCCCUAUGUCGA<br>((((.((((((((((((((((((((((((((((((                     |  |  |
| miRmR_28  | mRNA-miRNA<br>sequence<br>RNAfold<br>Mfold<br>AveRNA | GGGCCCGCCGCGCCAUGCCUGUGGCCGGCCC<br>(((((.((((()))))).))))<br>(((((.((((()))))).))))<br>(((((.((((()))))).))))                        |  |  |
| miRmR_42  | mRNA-miRNA<br>sequence<br>RNAfold<br>Mfold<br>AveRNA | CCGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCUGCGG<br>((((.((.((.(()).)).)).)))))<br>((((.((.((.(()).)).)))))))<br>((((.(.((.((.()).)).)))))))) |  |  |
| miRmR_50  | mRNA-miRNA<br>sequence<br>RNAfold<br>Mfold<br>AveRNA | GGUCUGGGCGCAGCGCAAGCUGACGGUACAGGCC<br>((((((((((()))).)).)))))<br>((((((((((()))).)).)))))<br>((((((((((()))).)))))))                |  |  |
| miRmR_348 | mRNA-miRNA<br>sequence<br>RNAfold<br>Mfold<br>AveRNA | GGGAGAGGGUUUAAUCAGUACGAAAGUACGGAUUGGAUCCGCAAGG<br>((((((((()))).)))))))))<br>((((((((  |  |  |

S-Table 4. Comparison of RNA secondary structure with different placeholders inserted in the binding site of mRNA-miRNA

sequence.

| RNA_ID    | item  | mRNA-miRNA sequence and<br>predicted secondary structures   |
|-----------|---|---|
| miRmR_16  | mRNA-miRNA<br>sequence<br>0 placeholder<br>2 placeholders<br>5 placeholders | GGCGUCGCACCUUCGGGUGAAGUCGCC<br>(((((((())))))))<br>(((((((())))))))<br>(((((((())))))))                                 |
| miRmR_28  | mRNA-miRNA<br>sequence<br>0 placeholder<br>2 placeholders<br>3 placeholders | GGGCCCGCCGCGCCAUGCCUGUGGCCGGCCC<br>(((((.((((()))))).))))<br>(((((.((((()))))).)))))<br>(((((.((((()))))).)))))         |
| miRmR_64  | mRNA-miRNA<br>sequence<br>0 placeholder<br>3 placeholders<br>4 placeholders | GAGGGUGGAACCGCGCUUCGGCGUCCCUC<br>((((((((()))))))))<br>((((((((())))))))  |
| miRmR_50  | mRNA-miRNA<br>sequence<br>0 placeholder<br>1 placeholder<br>3 placeholders  | GGUCUGGGCGCAGCGCAAGCUGACGGUACAGGCC<br>((((((((((()))).)).)))))<br>(((((((((((()))).)).)))))<br>((((((((((()))).)).))))) |
| miRmR_291 | mRNA-miRNA<br>sequence<br>0 placeholder<br>2 placeholders<br>4 placeholders | GGGAGAGGGUUUAAUAUAUACGAAAGUAGUCAUUGGAUCCGCAAGG<br>((((((((((()))))))))))  |

S-Table 5. The data for different algorithms and fingerprints with accuracy and roc\_auc.

|       | accuracy |        |        | roc_auc |        |        |        |        |
|-------|----------|--------|--------|---------|--------|--------|--------|--------|
| Model | morgan   |        | rdkit  |         | morgan |        | rdkit  |        |
|       | Mean     | STD    | Mean   | STD     | Mean   | STD    | Mean   | STD    |
| LR    | 0.7316   | 0.0211 | 0.7342 | 0.0228  | 0.5138 | 0.0375 | 0.5004 | 0.0364 |
| LDA   | 0.7290   | 0.0219 | 0.7308 | 0.0202  | 0.5943 | 0.0357 | 0.5996 | 0.0378 |
| KNN   | 0.8214   | 0.0194 | 0.8087 | 0.0184  | 0.8619 | 0.0213 | 0.8447 | 0.0224 |
| CART  | 0.8001   | 0.0169 | 0.7907 | 0.0227  | 0.7462 | 0.0191 | 0.7387 | 0.0295 |
| NB    | 0.3325   | 0.0567 | 0.6724 | 0.0335  | 0.4579 | 0.0355 | 0.5877 | 0.0465 |
| SVM   | 0.7525   | 0.0206 | 0.7671 | 0.0188  | 0.7385 | 0.0398 | 0.7394 | 0.0429 |
| RF    | 0.8413   | 0.0187 | 0.8383 | 0.0182  | 0.8702 | 0.0253 | 0.8731 | 0.0217 |

|    | RNA_ID     | Score    | Predicted probably |
|----|------------|----------|--------------------|
| 1  | miRmR_328  | 0.810833 | 1                  |
| 2  | miRmR_339  | 0.806667 | 1                  |
| 3  | miRmR _347 | 0.764167 | 1                  |
| 4  | miRmR _321 | 0.762500 | 1                  |
| 5  | miRmR _348 | 0.750833 | 1                  |
| 6  | miRmR _337 | 0.741667 | 1                  |
| 7  | miRmR _338 | 0.738167 | 1                  |
| 8  | miRmR _48  | 0.725000 | 1                  |
| 9  | miRmR _346 | 0.710000 | 1                  |
| 10 | miRmR _325 | 0.705667 | 1                  |
| 11 | miRmR _345 | 0.667917 | 1                  |
| 12 | miRmR _336 | 0.624333 | 1                  |
| 13 | miRmR _64  | 0.592500 | 1                  |
| 14 | miRmR _50  | 0.590000 | 1                  |
| 15 | miRmR _23  | 0.526667 | 1                  |
| 16 | miRmR _65  | 0.522500 | 1                  |
| 17 | miRmR _25  | 0.505000 | 1                  |
| 18 | miRmR _57  | 0.492500 | 0                  |
| 19 | miRmR _1   | 0.465000 | 0                  |
| 20 | miRmR _26  | 0.457500 | 0                  |

S-Table 6. The 20 predicted miRNA-mRNA interactions.